This work is licensed under a Creative Commons Attribution 4.0 International License.
HPRP-A1-GG-iRGD
General Information
DRACP ID DRACP00860
Peptide Name HPRP-A1-GG-iRGD
Sequence FKKLKKLFSKLWNWKGGCRGDKGPDC
Sequence Length 26
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| A549 | Lung adenocarcinoma | Carcinoma | IC50=21.6 µM | MTT assay | 24h | 1 |
| MDA-MB-231 | Breast adenocarcinoma | Carcinoma | IC50=15.2 µM | MTT assay | 24h | 1 |
| NCI-H460 | Lung large cell carcinoma | Carcinoma | IC50=12.9 µM | MTT assay | 24h | 1 |
| BGC-823 | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | IC50=14.8 µM | MTT assay | 24h | 1 |
| MCF-7 | Invasive breast carcinoma of no special type | Carcinoma | IC50=15.8 µM | MTT assay | 24h | 1 |
Hemolytic Activity Human red blood cells: MHC=125 μM, MHC: the minimum hemolytic concentration is the concentration of peptide that results in 10% hemolysis of human red blood cells (hRBCs).
Normal (non-cancerous) Cytotoxicity HUVEC: IC50=31.6 μM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C140H219N39O33S2
Absent amino acids AEHIMQTVY
Common amino acids K
Mass 348675
Pl 10.68
Basic residues 8
Acidic residues 2
Hydrophobic residues 7
Net charge 6
Boman Index -4955
Hydrophobicity -100.38
Aliphatic Index 45
Half Life
Mammalian: 1.1 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 11125
Absorbance 280nm 445
Polar residues 8
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 30592418
Title Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation
Doi 10.1021/acs.molpharmaceut.8b00854
Year 2019
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.